
AbbVie’s ADC win shows how pharma can break through in solid tumors
Antibody-drug conjugates have become a “choose your own adventure” tool in pharma R&D. Due to their versatility, the therapies have proved themselves as a potent weapon against many oncology indications, AstraZeneca’s vice president and head of …